Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients, today announced the close of its $28 million series A funding round. The Company also announces the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital.
The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies. The funds will also support recruitment efforts, building the Company’s senior leadership, experimental biology, and computational teams.
Mosaic’s use of advanced computational methods, while combining mining of large datasets with experimental approaches to identify and develop novel targeted therapies, completely reinvents the traditional approach to target and drug discovery. The Company’s bespoke relationship with the Wellcome Sanger Institute provides it unique access to deep scientific expertise, infrastructure, and biological assets.
Brian Gladsden joins Mosaic as CEO following a 25-year career in biopharmaceuticals, including 5 years with Bayer AG and 15 years with Novartis Oncology, where he was Senior Vice President and a member of the Worldwide Leadership Team, with responsibility for global commercialisation and strategy for the portfolio. Mr Gladsden has held various leadership positions, including country CEO, leading cancer therapeutic development and commercial launch across the US, Europe, Australia, South Korea and Japan.
Mosaic’s proprietary platform applies research from co-founder Dr Mathew Garnett’s Translational Cancer Genomics Laboratory at the Wellcome Sanger Institute. Dr Garnett is a Senior Group Leader at Sanger with over 20 years’ experience in genomics and cancer therapeutics, with past achievements including co-discovery of BRAF mutations in cancer and Werner Syndrome helicase as a target in MSI tumours.
Brian Gladsden, CEO, Mosaic Therapeutics, commented: “I believe that Mosaic is ideally positioned to resolve the complexity of cancer, to discover and develop targeted therapies that address areas of high unmet need. The people, platform, connection to a world-leading genomics research institute, and strong investor partnerships are truly best in class.
To receive funding from such high calibre investors is testament to the potential of Mosaic’s technology and multidisciplinary team, as well as the exceptional support provided by the Wellcome Sanger Institute.”
Alongside Dr Garnett, the Company was co-founded by Professor Emile Voest and Dr Adrian Ibrahim. Professor Voest is Professor of Medical Oncology, Chairman of the Board of Cancer Core Europe, Group Leader at the Netherlands Cancer Institute and Oncode Institute, and Independent Director of the Board of Sanofi S.A. Dr Ibrahim was formerly Head of Technology Translation at the Wellcome Sanger Institute, has 30 years’ experience across the discovery and development of cancer and genomics technologies, and has been involved in multiple genomics company spin-outs.
Dr Mathew Garnett, co-founder of Mosaic Therapeutics, added: “Mosaic is ready to lead the next wave of treatments for cancer, through the discovery of effective targeted therapies in molecularly-defined patients. Cancer is a complex disease and our platform, combining large-scale screening in advanced cancer models and cancer big data, gives Mosaic unprecedented clarity and insights. With high calibre investors, an experienced CEO, and solid scientific foundations, we’re building an exceptional team to deliver on our vision to develop safer and more effective medicines.”
Magdalena Jonikas, Lead Partner at Syncona Investment Management Limited and Director of Mosaic, said: “The unprecedented insights provided by the genomic revolution have enabled more targeted drug development, with drug targets being de-risked by genetics or data. This approach to drug discovery is a focus for us at Syncona and Mosaic is a great example of a company built around this concept. With a differentiated strategy that can accelerate entry to the clinic, and the potential for application in a number of oncology settings in cancers which have previously been difficult to treat, we are excited for the potential of this platform. The opportunity for the Company, and most importantly for patients, is significant. I am thrilled that Brian has joined Mosaic to lead the next stage of the Company’s growth, and look forward to building this business in partnership with its world-class team.”
